HomeCompareNPACF vs PFE

NPACF vs PFE: Dividend Comparison 2026

NPACF yields 5.15% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NPACF wins by $4943.14M in total portfolio value
10 years
NPACF
NPACF
● Live price
5.15%
Share price
$15.75
Annual div
$0.81
5Y div CAGR
98.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4943.19M
Annual income
$4,748,205,307.75
Full NPACF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — NPACF vs PFE

📍 NPACF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNPACFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NPACF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NPACF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NPACF
Annual income on $10K today (after 15% tax)
$437.47/yr
After 10yr DRIP, annual income (after tax)
$4,035,974,511.59/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, NPACF beats the other by $4,035,952,191.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NPACF + PFE for your $10,000?

NPACF: 50%PFE: 50%
100% PFE50/50100% NPACF
Portfolio after 10yr
$2471.62M
Annual income
$2,374,115,783.24/yr
Blended yield
96.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

NPACF
No analyst data
Altman Z
1.4
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NPACF buys
0
PFE buys
0
No recent congressional trades found for NPACF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNPACFPFE
Forward yield5.15%6.13%
Annual dividend / share$0.81$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR98.1%13.2%
Portfolio after 10y$4943.19M$49.6K
Annual income after 10y$4,748,205,307.75$26,258.71
Total dividends collected$4929.45M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NPACF vs PFE ($10,000, DRIP)

YearNPACF PortfolioNPACF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,720$1,019.55$9,153$693.39+$2.6KNPACF
2$14,752$2,212.19$8,593$849.25+$6.2KNPACF
3$20,940$5,155.44$8,336$1,066.78+$12.6KNPACF
4$35,955$13,548.57$8,437$1,384.80+$27.5KNPACF
5$81,541$43,069.29$9,013$1,875.40+$72.5KNPACF
6$268,086$180,837.48$10,306$2,680.72+$257.8KNPACF
7$1,387,603$1,100,750.50$12,820$4,101.38+$1.37MNPACF
8$12,032,987$10,548,251.93$17,673$6,826.70+$12.02MNPACF
9$182,226,986$169,351,690.09$27,543$12,591.86+$182.20MNPACF
10$4,943,188,183$4,748,205,307.75$49,560$26,258.71+$4943.14MNPACF

NPACF vs PFE: Complete Analysis 2026

NPACFStock

Quadient S.A. provides business solutions for customers through digital and physical channels in France and internationally. The company offers customer experience management, business process automation, mail-related solutions, and parcel locker solutions. It provides Quadient Inspire, a software solution that helps businesses design, manage, and send personalized, omnichannel communications in large volumes. The company also offers Quadient Impress, a multichannel outbound document management platform; YayPay, account receivable process automation solutions; and Beanworks, accounts payable solution automating error-prone manual processes. In addition, it provides lines of software and hardware for preparing and sending mails in low and high volumes. Further, the company operates a pick-up, drop-off solution that offers businesses and people who need to manage their deliveries and returns. Additionally, it distributes print finishing equipment, such as guillotines, binding machines, laminating machines, and paper folding machines; provides professional and maintenance services; shipping software solutions; and automated packaging solutions. It serves financial services, healthcare, higher education, insurance, public sectors/government, retail, service providers, shipping carriers, telecommunications, and utilities industries. The company was formerly known as Neopost S.A. and changed its name to Quadient S.A. in September 2019. Quadient S.A. was founded in 1924 and is headquartered in Bagneux, France.

Full NPACF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this NPACF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NPACF vs SCHDNPACF vs JEPINPACF vs ONPACF vs KONPACF vs MAINNPACF vs JNJNPACF vs MRKNPACF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.